Q1 2019 EPS Estimates for Kala Pharmaceuticals Inc Reduced by Analyst (KALA)

Kala Pharmaceuticals Inc (NASDAQ:KALA) – Equities researchers at Wedbush decreased their Q1 2019 earnings per share (EPS) estimates for shares of Kala Pharmaceuticals in a report released on Wednesday, January 16th. Wedbush analyst L. Moussatos now anticipates that the company will post earnings per share of ($0.46) for the quarter, down from their previous estimate of ($0.43). Wedbush has a “Buy” rating and a $51.00 price target on the stock. Wedbush also issued estimates for Kala Pharmaceuticals’ Q2 2019 earnings at ($0.56) EPS, Q3 2019 earnings at ($0.69) EPS, Q4 2019 earnings at ($0.67) EPS, FY2019 earnings at ($2.38) EPS, FY2020 earnings at ($1.51) EPS, FY2021 earnings at $2.09 EPS and FY2022 earnings at $7.13 EPS.

KALA has been the subject of a number of other reports. Wells Fargo & Co reiterated a “buy” rating and set a $15.00 price target (down from $19.00) on shares of Kala Pharmaceuticals in a research report on Thursday, October 4th. HC Wainwright set a $15.00 price target on shares of Kala Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, November 9th. ValuEngine downgraded shares of Kala Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, December 21st. JPMorgan Chase & Co. reduced their price target on shares of Kala Pharmaceuticals from $35.00 to $22.00 and set an “overweight” rating for the company in a research report on Wednesday, November 14th. Finally, BidaskClub downgraded shares of Kala Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 27th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $21.70.

KALA stock opened at $5.89 on Monday. Kala Pharmaceuticals has a 12-month low of $4.03 and a 12-month high of $18.30. The company has a debt-to-equity ratio of 0.30, a current ratio of 6.34 and a quick ratio of 6.27. The company has a market cap of $199.06 million, a PE ratio of -1.01 and a beta of 1.00.

Kala Pharmaceuticals (NASDAQ:KALA) last posted its quarterly earnings results on Thursday, November 8th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.01).

Several institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. increased its stake in shares of Kala Pharmaceuticals by 16.8% during the 3rd quarter. BlackRock Inc. now owns 1,105,361 shares of the company’s stock worth $10,910,000 after purchasing an additional 158,883 shares in the last quarter. Vanguard Group Inc increased its stake in shares of Kala Pharmaceuticals by 8.0% during the 3rd quarter. Vanguard Group Inc now owns 510,295 shares of the company’s stock worth $5,036,000 after purchasing an additional 37,738 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Kala Pharmaceuticals by 8.0% during the 3rd quarter. Vanguard Group Inc. now owns 510,295 shares of the company’s stock worth $5,036,000 after purchasing an additional 37,738 shares in the last quarter. Greylock Xii GP LLC purchased a new position in shares of Kala Pharmaceuticals during the 3rd quarter worth approximately $1,970,000. Finally, JPMorgan Chase & Co. increased its stake in shares of Kala Pharmaceuticals by 37.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 160,080 shares of the company’s stock worth $1,580,000 after purchasing an additional 43,599 shares in the last quarter. 47.58% of the stock is owned by institutional investors and hedge funds.

About Kala Pharmaceuticals

Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. Its product candidates include KPI-121 1.0%, which has completed Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; INVELTYS that has completed Phase III clinical trials for the temporary relief of the signs and symptoms of dry eye disease; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.

Featured Story: What does EPS mean?

Earnings History and Estimates for Kala Pharmaceuticals (NASDAQ:KALA)

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit